FDA approves Natpara(R) (parathyroid hormone) to control hypocalcemia
NPS Pharmaceuticals announced the FDA has approved Natpara® (parathyroid hormone) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015. January 23, 2015